Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEIES plus Stapokibart for type 2 chronic rhinosinusitis
ChiCTR2500107337Phase 4Recruiting
- Sponsor
- China-Japan Union Hospital of Jilin University
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of stapokibart in chronic rhinosinusitis (CRS), chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP) (2 arms), sponsored by China-Japan Union Hospital of Jilin University. Primary endpoint: Symptom score (VAS). Started Aug 2025; status: recruiting.
02
Drugs
stapokibart
03
Conditions
chronic rhinosinusitis (CRS)chronic rhinosinusitis with nasal polyps (CRSwNP)chronic rhinosinusitis without nasal polyps (CRSsNP)
Beyond the preview
Go deeper on ChiCTR2500107337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107337.